Results 51 to 60 of about 13,844,580 (194)

PBPK Modeling: Empowering Drug Development and Precision Dosing in China

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Physiologically based pharmacokinetic (PBPK) modeling, a cornerstone of model‐informed drug development and model‐informed precision dosing, simulates drug disposition in the human body by integrating physiological, biochemical, and physicochemical ...
Dongsheng Yang   +7 more
doaj   +1 more source

The integrated Lei‐CNS PBPK‐PD model effectively predicts clozapine brain disposition and D2 receptor occupancy in humans

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Clozapine, used for treatment‐resistant schizophrenia, has a narrow therapeutic window and highly variable plasma pharmacokinetics (PK), necessitating careful monitoring. Direct measurement of unbound brain PK in humans is unethical. To develop a physiologically based pharmacokinetic–pharmacodynamic (PBPK‐PD) model to predict clozapine brain ...
Mengxu Zhang   +3 more
wiley   +1 more source

Population Physiologically‐Based Pharmacokinetic Modeling to Determine Ontogeny: A Quantitative Clinical Pharmacology Example in Pediatric Rare Disease

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Pediatric physiologically‐based pharmacokinetic (PBPK) modelling plays an increasing role in selecting doses in children and addressing clinical pharmacology questions.
Yumi Cleary   +4 more
doaj   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling   +6 more
wiley   +1 more source

Whole-body PBPK Model Rate Equations.

open access: yes, 2016
Whole-body PBPK Model Rate Equations.
Alin Cosmanescu (3124272)   +7 more
core   +1 more source

Construction of PBPK model of quercetin and predicting pharmacokinetic behavior in humans

open access: yesZhongguo shipin weisheng zazhi
ObjectiveTo use physiologically based pharmacokinetic (PBPK) model to predict the tissue distribution of quercetin in human, and analyze its distribution and metabolic transformation process in different physiological compartments, so as to supplement ...
XU Nu   +5 more
doaj   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

open access: yesBMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim   +9 more
wiley   +1 more source

Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases

open access: yesScientific Reports
The purpose of this study was to develop and validate a physiologically based pharmacokinetic (PBPK) model combined with an EGFR occupancy (EO) model for osimertinib (OSI) to predict plasma trough concentration (Ctrough) and the intracranial time-course ...
Feng Liang   +3 more
doaj   +1 more source

Advancing Safety and Sustainability in Nanomaterials Industry: Methodological, Business, and Regulatory Implications

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT The rapid proliferation of chemicals and nanomaterials (CNMs) has resulted in significant cross‐sector innovation, delivering product enhancements such as improved UV protection and waterproof textiles. However, these advances present urgent challenges regarding human safety, environmental hazards, and regulatory compliance. Despite the recent
Alessandra Fiorucci   +4 more
wiley   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary   +59 more
wiley   +1 more source

Home - About - Disclaimer - Privacy